RATIONALE: @entity390 ( @entity390 ) is a poorly controlled side effect experienced by chemotherapy @entity1 . Currently, pharmacotherapy is restricted to @entity1245 anxiolytics, which have limited efficacy, have significant sedative effects and induce dependency. The non-psychoactive phytocannabinoid, @entity39568 ( @entity39569 ), has shown considerable efficacy in pre-clinical @entity390 models, however determination of its neuromotor tolerability profile is crucial to justify clinical investigation. Provisional evidence for appetite-stimulating properties also requires detailed investigation. OBJECTIVES: This study aims to assess the tolerability of @entity39569 in locomotor activity, motor coordination and muscular strength tests, and additionally for ability to modulate feeding behaviours. METHODS: Male Lister Hooded @entity35 administered @entity39569 (0.05-5  mg/kg; p.o.) were assessed in habituated open field (for locomotor activity), static beam and grip strength tests. A further study investigated whether these @entity39569 doses modulated normal feeding behaviour. Finally, evidence of anxiolytic-like effects in the habituated open field prompted testing of 5  mg/kg @entity39569 for anxiolytic-like activity in unhabituated open field, light/dark box and novelty-suppressed feeding (NSF) tests. RESULTS: @entity39569 had no adverse effects upon performance in any neuromotor tolerability test, however @entity8553 was observed in the habituated open field. Normal feeding behaviours were unaffected by any dose. @entity39569 (5  mg/kg) abolished the increased feeding latency in the NSF test induced by the 5-HT1AR antagonist, WAY-100,635, indicative of anxiolytic-like effects, but had no effect on @entity148 -like behaviour in the novel open field or light/dark box. CONCLUSIONS: @entity39569 is very well tolerated and devoid of the sedative side effect profile of @entity1245 , justifying its clinical investigation as a novel @entity390 treatment.

Neuromotor tolerability and behavioural characterisation of @entity39568 , a phytocannabinoid with therapeutic potential for anticipatory XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity390 :: ('MESH:D009325', 'Disease') :: ['AN', 'Anticipatory nausea'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity39568 :: ('MESH:C006884', 'Chemical') :: ['cannabidiolic acid'] @entity8553 :: ('MESH:C565779', 'Disease') :: ['anxiolytic-like behaviour'] @entity1245 :: ('MESH:D001569', 'Chemical') :: ['benzodiazepine', 'benzodiazepines'] @entity148 :: ('MESH:D001008', 'Disease') :: ['anxiety'] @entity39569 :: ('CHEBI:3359', 'Chemical') :: ['CBDA']
@entity390 :: (MESH:D009325,Disease) :: ['nausea']
